Mineralys Therapeutics, Inc. (MLYS)
25.60
-0.41
(-1.58%)
USD |
NASDAQ |
Aug 28, 16:00
25.60
0.00 (0.00%)
After-Hours: 20:00
Mineralys Therapeutics Cash from Operations (Quarterly) : -32.56M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -32.56M |
| March 31, 2026 | -39.47M |
| December 31, 2025 | -37.89M |
| September 30, 2025 | -28.87M |
| June 30, 2025 | -30.17M |
| March 31, 2025 | -45.49M |
| December 31, 2024 | -66.84M |
| September 30, 2024 | -50.19M |
| June 30, 2024 | -30.15M |
| Date | Value |
|---|---|
| March 31, 2024 | -19.14M |
| December 31, 2023 | -28.98M |
| September 30, 2023 | -19.03M |
| June 30, 2023 | -20.39M |
| March 31, 2023 | -12.78M |
| December 31, 2022 | -10.19M |
| September 30, 2022 | -6.988M |
| June 30, 2022 | -5.469M |
| March 31, 2022 | -6.578M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| MapLight Therapeutics, Inc. | -44.87M |
| Evommune, Inc. | -20.32M |
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -185.22M |
| Cash from Financing (Quarterly) | 243.26M |
| Free Cash Flow | -138.80M |
| Free Cash Flow Per Share (Quarterly) | -0.3842 |
| Free Cash Flow to Equity (Quarterly) | -130.17M |
| Free Cash Flow to Firm (Quarterly) | -32.56M |
| Free Cash Flow Yield | -6.80% |